In addition to the effects on sodium and water homeostasis, pharmacological administration of DPPIV inhibitors confers renoprotection by reducing proteinuria and ameliorating renal damage in experimental models of diabetic nephropathy (Liu et al., 2012; Kanasaki et al., 2014; Eun Lee et al., 2016). The gene discussed is DPP4; the disease is diabetic kidney disease.